SQZ Biotechnologies Company (SQZB)
SQZ Biotechnologies Company operates in the Biotechnology industry of the Healthcare sector, headquartered in Watertown, MA, US. The stock last traded at $0.02, up 0.00% on the session, giving a market capitalisation of $707,787. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of -377.9%. Its beta of 0.34 implies it has historically moved less than the broad market.
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
SQZ Biotechnologies Company is most often compared with the following Healthcare names: